Pasithea Therapeutics (KTTA) investor relations material

Introduction and agenda

• Event focused on NF1, affecting ~1 in 3,000 people, and the development of PAS-004 for plexiform and cutaneous neurofibromas; agenda covered molecule and clinical data, clinician perspectives, trial design, and commercial opportunity.

• Presentations were led by CMO Kartik Krishnan, Dr. Rebecca Brown of UAB, dermatologist Dr. Kavita Sarin of Stanford, and CEO Tiago Reis Marques.

KOL background and credentials

• Dr. Rebecca Brown directs UAB’s Neurofibromatosis and Schwannomatosis Program and discussed plexiform neurofibromas and their clinical management.

• Dr. Kavita Sarin is a Stanford dermatologist, directs the Skin Cancer Genetics Clinic at Stanford Cancer Institute, and co-leads the REiNS Cutaneous Neurofibroma Working Group.

Market insights and analysis

• U.S. plexiform neurofibroma estimates included ~68,000 people with NF1 and PN, ~51,000 symptomatic, and ~48,000 not receiving MEK inhibitor treatment; ~13% of PN patients face risk of malignant sarcoma.

• Existing MEK inhibitors can require dose reductions or discontinuation: trial data cited ~17% dose reductions and ~12% discontinuations; real-world discontinuation was described as higher.

• cNFs affect >95% of adults with NF1; a Stanford photo cohort found two-thirds had >100 lesions and one-third >500. Appearance, location, number, and size were major patient concerns.

• U.S. cNF population was estimated at ~150,000, with >80,000 having >50 lesions; market research suggested treatment interest would rise to 40%-50% with an approved option.

• Physician interviews viewed 20%-30% cNF volume reduction as potentially meaningful; interviewed patients rated current options 2.3/7 and interest in a novel treatment 5.5/7, preferring tablets but emphasizing tolerability.